Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

RPS calls on Welsh government to support records access

RPS Wales hopes to influence political manifestos ahead of the Welsh Assembly elections in May 2016

The Royal Pharmaceutical Society (RPS) is using the build-up to next year's Welsh Assembly elections to push for the country's pharmacists to gain access to patient records.

Welsh pharmacists are currently unable to view individual care records, which limits their ability to make clinical decisions and “restricts the potential for meaningful dialogue” with patients and GPs, RPS Wales said in a vision document published yesterday (October 26).

It hopes the document will “help shape the party political manifestos for the 2016 Welsh election”.

Online access to patient records would allow pharmacists to support patients with chronic conditions, common ailments, minor injuries and “non-life threatening emergencies”, RPS Wales said. It could also pave the way for the development of new services, it said in the document, which also makes the case for a chronic conditions medication service.

The proposed chronic medication service would see pharmacists and GPs working together to produce a medication plan, RPS Wales explained. Pharmacists would offer "structured support, advice and review of their medicines" on an ongoing basis, which would be aided by access to patient records and prescribing powers, it added. The service could reduce hospital admissions and allow patients to live “as independently as possible in their own communities”, it stressed. 

RPS Wales added that existing strategies such as the discharge medicines review service must "continue to be supported" to reduce medication-related errors and improve appropriate prescribing.

It also emphasised the need to "fully integrate" pharmacists into NHS multidisciplinary teams, which it said would "harness the expertise of pharmacists and utilise their clinical and prescribing skills". The organisation pointed to "around 130" Welsh pharmacists trained as independent prescribers, who are "ready and waiting to tackle the growing demands on primary care services".

Politicians should "commit" to the proposals

RPS Welsh Pharmacy Board chair Suzanne Scott-Thomas urged political parties to commit to the proposals, which would “improve patient safety, increase access to services and ensure all health professionals can work at the top of their game”.

RPS Wales said it is currently engaging with the Welsh political parties to “outline the benefits” of its proposals ahead of the assembly elections in May.

In June, the UK government committed £7.5 million to partially fund the rollout of summary care record access to every pharmacy in England.
 


How would read-write records access improve the service you offer patients?

We want to hear your views, but please express them in the spirit of a constructive, professional debate. For more information about what this means, please click here to see our community principles and information

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD007786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel